Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not sufficient. Of the targeted therapies, Novartis’s interleukin (IL)-17 inhibitor Cosentyx; Janssen’s IL-12/23 inhibitor Stelara; and AbbVie’s TNF-α inhibitor Humira have dominated the landscape. However, patient shares of established targeted agents are increasingly being challenged by newer therapies, including AbbVie’s latest-in-class IL-23 inhibitor Skyrizi and Eli Lilly’s Taltz. We also expect Amgen’s Otezla, the only oral targeted therapy with a notable patient share in psoriasis, to face fierce competition from Bristol Myers Squibb’s Sotyktu, which was approved in September 2022.
Markets covered: United States
Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis, UCB
Key drugs: Cimzia, Cosentyx, Duobrii, Enbrel, Humira, infliximab biosimilars, Otezla, Remicade, Skyrizi, Stelara, Taltz, Tremfya
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.